This review article explores the dynamic field of radiopharmaceuticals, where innovative
developments arise from combining radioisotopes and pharmaceuticals, opening up …

The field of theranostics is rapidly advancing, driven by the goals of enhancing patient care.
Recent breakthroughs in artificial intelligence (AI) and its innovative theranostic applications …

Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen
(PSMA) ligands have demonstrated promising results for the treatment of metastatic …

Trustworthiness is a core tenet of medicine. The patient–physician relationship is evolving
from a dyad to a broader ecosystem of health care. With the emergence of artificial …

Radiotheranostics refers to the pairing of radioactive imaging biomarkers with radioactive
therapeutic compounds that deliver ionizing radiation. Given the introduction of very …

Background Prostate-specific membrane antigen (PSMA) PET/CT imaging is widely used for
quantitative image analysis, especially in radioligand therapy (RLT) for metastatic castration …

Purpose Accurate dosimetry is critical for ensuring the safety and efficacy of
radiopharmaceutical therapies. In current clinical dosimetry practice, MIRD formalisms are …

Targeted radiation therapy (TRT) is a strategy increasingly adopted for the treatment of
different types of cancer. The urge for optimization, as stated by the European Council …

Radioligand therapy is an emerging and effective treatment option for various types of
malignancies, but may be intricately linked to hematological side effects such as anemia …

The task of clinical interpretation of medical images starts with the scanning of the presented
image to detect the suspicious finding (“observation” in RadLex terminology (RID5) 1 which …